Remarkable efficacy of evenamide, a glutamate antagonist, as an add-on to antipsychotics in patients with treatment resistant schizophrenia (TRS): results from a one-year, open-label, dose-comparative, randomized, treatment trial

[P501] Remarkable efficacy of evenamide, a glutamate antagonist, as an add-on to antipsychotics in patients with treatment resistant schizophrenia (TRS): results from a one-year, open-label, dose-comparative, randomized, treatment trial

*Ravi Anand¹, Alessio Turolla², Giovanni Chinellato², Richard Hartman³ (1. Anand Pharma Consulting, 2. Newron Pharmaceuticals SpA, 3. NeurWrite LLC)

Keywords:Treatment resistant schizophrenia, long-term treatment, glutamate, add-on treatment, evenamide

Abstract password authentication.
Password is required to view the abstract. Please enter a password to authenticate.